Abstract Both BLISS-52 and BLISS-76 international phase III trials in Systemic Lupus
Erythematosus (SLE) met their primary outcomes; however, they were not designed to …

Background Belimumab, the first biologic approved for the treatment of systemic lupus
erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE …

During the last decades, there has been an increased interest in the discovery and
validation of biomarkers that reliably reflect specific aspects of lupus. Although many …

NGAL holds promise as a versatile biomarker in SLE whereas urine ALCAM, CD163 and
VCAM-1 displayed good performance as biomarkers in LN. The overall lack of concerted …

Serological and proteomic biomarkers can help clinicians diagnose rheumatic diseases
earlier and assess disease activity more accurately. These markers have been incorporated …

Objective Systemic lupus erythematosus (SLE) is a multifaceted disease characterized by
immune dysregulation and unpredictable disease activity. This study sought to evaluate the …

Objectives Patients with SLE are often exposed to prolonged immunosuppression since few
data on flare recurrence in remitted patients who discontinued immunosuppressants are …

Systemic lupus erythematosus (SLE), the prototypic systemic autoimmune disease, follows a
chronic disease course, punctuated by flares. Disease flares often occur without apparent …

Autophagy is a lysosomal pathway for the degradation of damaged proteins and intracellular
components that promotes cell survival under specific conditions. Apoptosis is, in contrast, a …

Objectives Whether immunosuppressive therapy may be safely withdrawn in lupus nephritis
(LN) is still unclear. We assessed rate and predictors of flare after IS withdrawal in patients …